How Long Do Mushrooms Stay in Your System for a Drug Test?

Psilocybin mushrooms clear the body quickly compared to most other recreational substances. In urine, psilocin (the active compound your body produces from psilocybin) typically drops below detectable levels within about 24 hours of a single oral dose. And the more practical reality for most people worried about workplace screening is that standard drug test panels do not look for psilocybin or psilocin at all. Specialized testing does exist, though, and the detection window varies by sample type and individual factors in ways worth understanding.

How Your Body Processes Psilocybin

Psilocybin itself is not the molecule that makes you trip. It is a prodrug, meaning your body converts it into something else before it becomes active. Enzymes in your gut and liver strip off a phosphate group, turning psilocybin into psilocin, which is the compound that actually interacts with serotonin receptors in your brain.¹ This conversion happens fast. After swallowing a dose, psilocin levels in your blood peak roughly one and a half to two hours later.²

Once psilocin is circulating, the body works to eliminate it through two main pathways. One route breaks it down further into an inactive byproduct. The other attaches a sugar molecule to it (a process called glucuronidation), making it water-soluble enough to flush out through the kidneys. That glucuronidated form ends up being the main thing excreted in urine.³ The glucuronidation happens primarily through specific liver and intestinal enzymes.⁴

The elimination half-life of psilocin in blood, which is how long it takes for the concentration to drop by half, ranges from about 1.5 to 3 hours depending on the study.⁵⁶ One study noted an extended tail of elimination in some participants, possibly because the glucuronidated form can slowly convert back to free psilocin before being cleared.⁶ Even so, within roughly 6 to 8 hours, blood levels are very low. This is noticeably faster than cannabis, amphetamines, or most other substances that people worry about before drug tests.

Urine Testing and the 24-Hour Window

Urine is the most relevant matrix for anyone facing a drug screen, so this is where the details matter most. In a controlled study where participants took a known oral dose of psilocybin, researchers collected urine at timed intervals and measured psilocin concentrations. The peak appeared in the 2-to-4-hour collection window, with concentrations reaching up to 870 micrograms per liter. By 24 hours after the dose, levels had usually fallen to the limit of quantitation, around 10 micrograms per liter.⁷

That 24-hour figure is the number most commonly cited, and it holds up well for a single typical dose. But there are caveats. The controlled study used pharmaceutical-grade psilocybin at a known dose, and individual variation in metabolism, body composition, hydration, and kidney function could stretch or shrink the window. Someone who took a large dose, or who has slower-than-average metabolism, might remain detectable somewhat longer. That said, even in a worst-case scenario, urine is unlikely to test positive for psilocin more than a couple of days after a single use. Psilocin simply does not accumulate in the body the way fat-soluble drugs like THC do.

There is one lab-side complication worth understanding. Because most psilocin gets excreted in its glucuronidated form rather than as free psilocin, a lab needs to perform a hydrolysis step, essentially breaking the glucuronide bond to release the psilocin before measuring it. If a lab skips this step, it can miss the compound entirely. One study found that free psilocin was undetectable in a mushroom user’s urine without hydrolysis, but after enzymatic treatment, the concentration measured 3.55 micrograms per milliliter.⁸ This means that the detection window depends not just on your biology but on how carefully the lab processes the sample.

Why Standard Drug Panels Usually Do Not Detect Mushrooms

The typical workplace or probation drug screen is an immunoassay panel, commonly testing for five or ten substance classes: amphetamines, cannabinoids, cocaine, opioids, and PCP being the standard five, sometimes expanded to include benzodiazepines, barbiturates, and a few others. Psilocybin and psilocin are not included in any standard panel. A routine pre-employment drug test will not flag mushroom use.

This is not just an oversight. Immunoassays work by using antibodies that bind to specific drug molecules or their metabolites, and psilocin’s structure is different enough from the substances on standard panels that it does not trigger a positive result. Research confirms this: the amphetamine and methamphetamine immunoassay has low cross-reactivity with psilocin.⁹ A separate study developing a psilocin-specific immunoassay found that common drugs of abuse like THC, cocaine, morphine, and amphetamine showed negligible cross-reactivity with psilocin, in the range of 0.01 to 2 percent.¹⁰

That said, specialized testing does exist. If someone has specific reason to suspect mushroom use, or if a forensic investigation requires it, a lab can run targeted analysis using liquid chromatography coupled with tandem mass spectrometry. These instruments can detect psilocin at concentrations as low as 0.1 nanograms per milliliter in plasma.¹¹ Certain drug court programs, military branches, or treatment-center protocols might order this kind of extended panel. But it has to be specifically requested and paid for. A random employer drug screen is not doing it.

Blood and Plasma Testing

Blood draws are less common than urine screens for routine drug testing, but they are used in clinical research, emergency medicine, and some forensic contexts. The detection window in blood is narrower than in urine because psilocin clears from the bloodstream faster than it takes the kidneys to finish flushing it out. Given elimination half-lives between roughly 1.5 and 3 hours, blood levels fall below detectable thresholds within about 6 to 8 hours for most people after a standard dose.⁵

Validated analytical methods for measuring psilocin and its metabolites in plasma have been developed for clinical trials, with accuracy and precision well within acceptable ranges.¹² In practical terms, though, a blood test is only going to catch psilocin use if the sample is drawn within a few hours of ingestion. By the time someone shows up at a clinic the next morning, blood levels are typically gone.

Saliva Testing

Oral fluid testing has been gaining traction for roadside checks and some workplace programs because it is non-invasive and harder to adulterate. For mushrooms, the science is still in early stages. Researchers have developed methods sensitive enough to detect psilocin in saliva at concentrations as low as 0.05 nanograms per milliliter.¹³ When they tested authentic samples collected from volunteers at music festivals, psilocin concentrations ranged from 0.08 to 36.4 nanograms per milliliter, though the median was quite low at 0.15 nanograms per milliliter.¹³

A key limitation here is that these festival samples were collected at unknown times after ingestion, so the data do not map neatly onto a detection-window timeline. Given how quickly psilocin clears from blood, and given that oral fluid concentrations generally track blood levels, the window for saliva detection is probably in the range of several hours at most. Saliva testing for psilocin is not currently part of any standard roadside or workplace protocol, but the validated methods suggest it could become feasible as testing technology spreads.

Hair Testing

Hair testing offers the longest possible detection window for almost any substance, because traces get incorporated into the hair shaft as it grows and can remain there for months. For psilocybin mushrooms, hair testing is technically possible but comes with significant practical limitations.

Researchers in one case identified psilocin in the hair of a repeat mushroom user at very low concentrations, measured in single-digit picograms per milligram of hair across three one-centimeter segments.¹⁴ A separate study reported higher concentrations, around 150 to 161 picograms per milligram, in two suspected users and described their method as the most sensitive available for this purpose.¹⁵ The paper titled “Pitfalls and Limitations” is instructive: the concentrations involved are extremely low, pushing the boundaries of even the most sensitive instruments. Psilocybin itself was not detected in hair in one study, only its metabolite psilocin.¹⁵

In practice, hair testing for psilocin is a forensic research tool, not something you would encounter in a workplace drug test. The concentrations are so tiny that routine hair panels, which are already uncommon and expensive, would not pick them up without highly specialized instrumentation and protocols. A person worried about a standard hair test should know that psilocin is not one of the analytes being screened.

The Sample Stability Problem

One factor that works strongly in favor of anyone worried about detection is that psilocin is chemically fragile. It degrades rapidly once outside the body, even in collected samples waiting to be analyzed. At room temperature, psilocin in whole blood degraded by 46 to 66 percent within a single day, and by 88 to 99 percent within three days. Refrigeration did not help much: at 4°C, degradation reached 66 to 76 percent after one day. Even frozen at negative 20°C, up to half the psilocin was lost within a month, and over 90 percent was gone within three months.¹⁶

The implication is stark. In forensic casework, psilocin that was genuinely present at the time of sample collection may completely vanish before the lab gets around to measuring it. This is one reason why researchers have been investigating psilocin glucuronide as an alternative biomarker. The glucuronidated form appears to be much more stable than free psilocin, which could make it a more reliable indicator of past psilocybin use.¹⁶ For the moment, though, most testing protocols still target free psilocin, meaning that delays between sample collection and analysis work against detection.

Individual Factors That Affect How Long You Test Positive

No two people metabolize psilocybin at exactly the same rate, and several factors can shift the window in either direction.

• Dose: Higher doses produce higher peak concentrations in blood and urine, which take longer to fall below detection thresholds. Someone who ate a large amount of mushrooms will stay positive longer than someone who took a low dose.
• Frequency of use: Repeated dosing does not cause meaningful accumulation of psilocin in the body because its half-life is too short. But frequent use may be more detectable in hair.
• Body composition: Psilocin is water-soluble, not fat-soluble, so body fat percentage plays a much smaller role than it does with cannabis. Hydration and kidney function are probably more relevant.
• Liver enzyme activity: The glucuronidation step is handled by specific liver enzymes. People with naturally faster or slower activity in those enzymes will clear psilocin at different rates.⁴
• Food intake: Taking mushrooms on a full stomach slows absorption, which can delay peak levels and slightly extend the overall timeline, though the total amount absorbed does not change dramatically.

The extended elimination phase observed in some participants in pharmacokinetic studies hints that genetic differences in enzyme activity can meaningfully stretch the tail end of detection.⁶ Still, even in slower metabolizers, the window is unlikely to extend beyond a few days in urine for a single use.

How Mushrooms Compare to Other Substances on Drug Tests

The contrast with other recreational drugs is dramatic. Cannabis metabolites can remain detectable in urine for weeks in regular users, partly because THC is fat-soluble and slowly leaches out of adipose tissue. Amphetamines typically show up for two to four days. Cocaine metabolites persist for around three days in casual users. Psilocin, by contrast, clears within about a day and is not even being looked for on the standard panel. This combination of rapid elimination and absent testing makes mushrooms one of the hardest recreational substances to catch on a drug screen.

There is sometimes confusion about whether mushrooms can trigger a false positive for another substance. The research is reassuring here. When tested against immunoassays designed for amphetamines, THC, cocaine, and morphine, psilocin showed negligible cross-reactivity, all at or below 2 percent.¹⁰ The only class of compounds that showed meaningful cross-reactivity in one assay study was tricyclic neuroleptics with a specific chemical side chain, which is irrelevant for most people taking mushrooms recreationally.¹⁰ In short, mushrooms will not cause you to fail a test for something else.

What About Amanita Mushrooms

Not all psychoactive mushrooms contain psilocybin. Amanita muscaria and Amanita pantherina produce their effects through different compounds entirely, primarily ibotenic acid and muscimol. These substances are rapidly absorbed from the gut and readily excreted in urine.¹⁷ Detection requires its own specialized analytical method, typically gas chromatography with mass spectrometry, and like psilocin, these compounds are not part of any standard drug panel.

Amanita mushrooms occupy a different legal niche in many jurisdictions as well: in several U.S. states, for instance, muscimol-containing mushrooms are not explicitly scheduled, unlike psilocybin mushrooms. Anyone using Amanita species and worrying about drug testing should know they face a separate set of detection and legal considerations from those using psilocybin mushrooms. The pharmacology, the metabolites, and the analytical methods are all different. The one commonality is that neither type shows up on a standard screen.

When Specialized Testing Is Most Likely

If standard workplace panels do not include psilocin, who is actually ordering these specialized tests? The most common scenarios are forensic investigations, where a death or accident has occurred and toxicologists want a comprehensive picture of what was in the person’s system. Clinical research settings also run these tests to track pharmacokinetics during psilocybin therapy trials. Some drug court programs or specialized probation conditions may require extended panels, though this is the exception rather than the rule. Military drug testing programs occasionally expand their panels beyond the standard, though psilocybin screening is still uncommon even there.

The expense and complexity of targeted psilocin testing makes mass screening impractical. These assays require liquid chromatography with tandem mass spectrometry, instruments that cost hundreds of thousands of dollars and need trained operators.¹² The per-sample cost is substantially higher than a standard immunoassay panel. For routine employment or insurance testing, there is simply no economic incentive to add psilocin to the list. That could change if psilocybin use becomes far more common or if regulatory pressure shifts, but for now, specialized testing remains rare outside of research and forensic contexts.